Description of Biogen Inc's Business Segments

Biogen Inc. is a prominent biotechnology company that is at the forefront of developing and commercializing groundbreaking therapies aimed at treating neurological and neurodegenerative diseases. The company maintains a commitment to addressing significant unmet medical needs, particularly in the arena of multiple sclerosis (MS), while also advancing its research endeavors in other related therapeutic areas. Below is a detailed overview of the segments, products, and services Biogen offers.

Product Portfolio

1. Multiple Sclerosis (MS) Treatments
Biogen has established itself as a leader in the development of therapies targeted at various forms of multiple sclerosis, particularly relapsing forms of the disease. The company’s key products in this category include:

- AVONEX:
- AVONEX is a recombinant interferon beta-1a that is administered intramuscularly for the treatment of relapsing forms of multiple sclerosis. This medication has demonstrated efficacy in reducing the frequency of relapses and slowing the progression of disability in MS patients. Since its launch in the U.S. in 1996 and in Europe in 1997, AVONEX has become one of the most widely prescribed MS therapies worldwide. The product is available in both pre-filled syringes and dry powder forms, facilitating ease of use for patients, especially those who may have difficulty with manual dexterity.

- TYSABRI:
- TYSABRI (natalizumab) is a monoclonal antibody that was approved for treating relapsing forms of MS. It functions by inhibiting the migration of immune cells into the central nervous system, thereby reducing inflammation and the formation of lesions. TYSABRI was first launched in 2004 and is also indicated for the treatment of Crohn’s disease. Initially, the product faced market access challenges due to safety concerns surrounding progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection. After extensive safety evaluations, TYSABRI was reintroduced with stringent risk management protocols.

- FAMPYRA:
- FAMPYRA (fampridine) is designed to improve walking ability in adults with MS, addressing a crucial aspect of mobility that many patients struggle with. This drug is the first of its kind focusing specifically on enhancing walking ability in individuals with MS. FAMPYRA has been successfully launched in several European nations and Australia and has shown significant efficacy in helping patients improve their mobility.

Other Therapeutics
Biogen also offers therapies beyond MS, which help address a broader range of neurological and autoimmune diseases:

- RITUXAN:
- Developed in collaboration with Genentech, RITUXAN (rituximab) is a monoclonal antibody utilized for treating conditions like non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and ANCA-associated vasculitis. This drug targets CD20-positive B cells and has a pivotal role in the therapeutic areas of oncology and immunology.

Research and Development
Biogen invests heavily in research and development to expand its therapeutic portfolio. The company dedicates resources to advancing treatment options for various neurological diseases beyond MS, including spinal muscular atrophy (SMA), Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS). Biogen is also active in the development of biosimilars, aiming to increase patient access to biological treatments and ensure affordability.

Services
In addition to its pharmaceutical offerings, Biogen provides a range of services to enhance patient care and treatment adherence:

- Patient Support Programs:
- Biogen has implemented several programs to assist patients through their treatment journeys, from initial diagnosis through to ongoing condition management. These programs include educational resources, counseling, and financial assistance, which are crucial for ensuring access to therapies and helping patients manage their conditions effectively.

- Collaborative Programs:
- Biogen collaborates with healthcare professionals, patient advocacy organizations, and research institutions to facilitate drug development, engage in real-world evidence studies, and support healthcare provider initiatives. This collaborative approach helps improve treatment outcomes and fosters innovation.

- Telehealth Initiatives:
- The company is leveraging telehealth solutions to enhance patient experiences by allowing care to be delivered remotely. This has become increasingly important, especially in light of the COVID-19 pandemic, as it offers patients easier access to healthcare services while minimizing the need for in-person visits.

Future Directions
Biogen remains focused on expanding its treatment portfolio for neurological diseases, with ongoing clinical trials investigating new and novel therapies. The company is dedicated to advancing personalized medicine approaches, utilizing genetic and biomarker information to enable precise treatment targeting based on individual patient profiles.

In essence, Biogen Inc. is a vital player in the biotechnology industry, particularly known for its innovative treatments for multiple sclerosis and its dedication to addressing other serious neurological conditions through continuous research and supportive patient services.

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Composition of Biogen Inc Revenues by Segments


Product revenue net	70.72 %	of total Revenue
Product revenue net U S	33.87 %	of total Revenue
Product revenue net Rest of World	36.85 %	of total Revenue
MS Product	38.64 %	of total Revenue
MS Product Revenues U S	22.58 %	of total Revenue
MS Product Revenues Rest of World	16.07 %	of total Revenue
Fumarate	11.64 %	of total Revenue
Fumarate U S	7.46 %	of total Revenue
Fumarate Rest of World	4.19 %	of total Revenue
TECFIDERA	4.42 %	of total Revenue
TECFIDERA U S	1.27 %	of total Revenue
TECFIDERA Rest of World	3.15 %	of total Revenue
VUMERITY	7.22 %	of total Revenue
VUMERITY U S	6.19 %	of total Revenue
VUMERITY Rest of World	1.03 %	of total Revenue
Interferon	9.18 %	of total Revenue
Interferon U S	5.36 %	of total Revenue
Interferon Rest of World	3.82 %	of total Revenue
AVONEX	6.59 %	of total Revenue
AVONEX U S	4.38 %	of total Revenue
AVONEX Rest of World	2.21 %	of total Revenue
PLEGRIDY	2.6 %	of total Revenue
PLEGRIDY U S	0.98 %	of total Revenue
PLEGRIDY Rest of World	1.61 %	of total Revenue
TYSABRI	17.82 %	of total Revenue
TYSABRI U S	9.76 %	of total Revenue
TYSABRI Rest of World	8.06 %	of total Revenue
Rare Disease Product Revenue	22.49 %	of total Revenue
Rare Disease Product Revenue U S	9.06 %	of total Revenue
Rare Disease Product Revenue Rest of World	13.43 %	of total Revenue
SPINRAZA	15.09 %	of total Revenue
SPINRAZA U S	5.74 %	of total Revenue
SPINRAZA Rest of World	9.36 %	of total Revenue
SKYCLARYS	6.08 %	of total Revenue
SKYCLARYS U S	2.9 %	of total Revenue
SKYCLARYS Rest of World	3.18 %	of total Revenue
QALSODY	1.31 %	of total Revenue
QALSODY U S	0.42 %	of total Revenue
QALSODY Rest of World	0.89 %	of total Revenue
Biosimilars	7.35 %	of total Revenue
Biosimilars Rest of World	7.35 %	of total Revenue
BENEPALI	4.93 %	of total Revenue
BENEPALI Rest of World	4.93 %	of total Revenue
IMRALDI	2 %	of total Revenue
IMRALDI Rest of World	2 %	of total Revenue
FLIXABI	0.42 %	of total Revenue
FLIXABI Rest of World	0.42 %	of total Revenue
Other	2.24 %	of total Revenue
Other U S	2.23 %	of total Revenue
Other Rest of World	0 %	of total Revenue
ZURZUVAE	2.24 %	of total Revenue
ZURZUVAE U S	2.23 %	of total Revenue
ZURZUVAE Rest of World	0 %	of total Revenue
Alzheimer s collaboration revenue	2.4 %	of total Revenue
Alzheimer s Collaboration	2.4 %	of total Revenue
Distributor One	0 %	of total Revenue
Distributor Two	0 %	of total Revenue
Genentech	0.29 %	of total Revenue
Royalty Attributed To OCREVUS	12.8 %	of total Revenue
Revenue from anti-CD20 therapeutic programs	16.91 %	of total Revenue
Contract manufacturing revenue	9.57 %	of total Revenue
Royalty and other revenue	0.39 %	of total Revenue
Contract manufacturing royalty and other revenue	9.96 %	of total Revenue
Reportable Segment	100 %	of total Revenue

Q1 three months ended (Mar 31 2026)
Revenues by Business Segments	Revenues (in millions $)	% (of total Revenues)
Product revenue net	1,752.30	70.72 %
Product revenue net U S	839.20	33.87 %
Product revenue net Rest of World	913.10	36.85 %
MS Product	957.50	38.64 %
MS Product Revenues U S	559.40	22.58 %
MS Product Revenues Rest of World	398.10	16.07 %
Fumarate	288.50	11.64 %
Fumarate U S	184.80	7.46 %
Fumarate Rest of World	103.70	4.19 %
TECFIDERA	109.50	4.42 %
TECFIDERA U S	31.40	1.27 %
TECFIDERA Rest of World	78.10	3.15 %
VUMERITY	179.00	7.22 %
VUMERITY U S	153.40	6.19 %
VUMERITY Rest of World	25.60	1.03 %
Interferon	227.50	9.18 %
Interferon U S	132.80	5.36 %
Interferon Rest of World	94.70	3.82 %
AVONEX	163.20	6.59 %
AVONEX U S	108.50	4.38 %
AVONEX Rest of World	54.70	2.21 %
PLEGRIDY	64.30	2.6 %
PLEGRIDY U S	24.30	0.98 %
PLEGRIDY Rest of World	40.00	1.61 %
TYSABRI	441.50	17.82 %
TYSABRI U S	241.80	9.76 %
TYSABRI Rest of World	199.70	8.06 %
Rare Disease Product Revenue	557.20	22.49 %
Rare Disease Product Revenue U S	224.50	9.06 %
Rare Disease Product Revenue Rest of World	332.70	13.43 %
SPINRAZA	374.00	15.09 %
SPINRAZA U S	142.20	5.74 %
SPINRAZA Rest of World	231.80	9.36 %
SKYCLARYS	150.70	6.08 %
SKYCLARYS U S	71.80	2.9 %
SKYCLARYS Rest of World	78.90	3.18 %
QALSODY	32.50	1.31 %
QALSODY U S	10.50	0.42 %
QALSODY Rest of World	22.00	0.89 %
Biosimilars	182.20	7.35 %
Biosimilars Rest of World	182.20	7.35 %
BENEPALI	122.10	4.93 %
BENEPALI Rest of World	122.10	4.93 %
IMRALDI	49.60	2 %
IMRALDI Rest of World	49.60	2 %
FLIXABI	10.50	0.42 %
FLIXABI Rest of World	10.50	0.42 %
Other	55.40	2.24 %
Other U S	55.30	2.23 %
Other Rest of World	0.10	0 %
ZURZUVAE	55.40	2.24 %
ZURZUVAE U S	55.30	2.23 %
ZURZUVAE Rest of World	0.10	0 %
Alzheimer s collaboration revenue	59.50	2.4 %
Alzheimer s Collaboration	59.50	2.4 %
Distributor One	0.00	0 %
Distributor Two	0.00	0 %
Genentech	7.20	0.29 %
Royalty Attributed To OCREVUS	317.20	12.8 %
Revenue from anti-CD20 therapeutic programs	419.10	16.91 %
Contract manufacturing revenue	237.20	9.57 %
Royalty and other revenue	9.70	0.39 %
Contract manufacturing royalty and other revenue	246.90	9.96 %
Reportable Segment	2,477.80	100 %
Total	2,477.80	100 %

Q1 three months ended (Mar 31 2026)
Revenue Growth rates by Segment	Y/Y Revenue %	Q/Q Revenue %
Product revenue net	1.49 %	-
Product revenue net U S	11.33 %	-
Product revenue net Rest of World	-6.13 %	-
MS Product	0.47 %	-
MS Product Revenues U S	14.07 %	-
MS Product Revenues Rest of World	-13.94 %	-
Fumarate	-16.35 %	-
Fumarate U S	17.78 %	-
Fumarate Rest of World	-44.84 %	-
TECFIDERA	-46.87 %	-
TECFIDERA U S	-21.11 %	-
TECFIDERA Rest of World	-53.04 %	-
VUMERITY	28.96 %	-
VUMERITY U S	31 %	-
VUMERITY Rest of World	17.97 %	-
Interferon	0.53 %	-
Interferon U S	0.08 %	-
Interferon Rest of World	1.18 %	-
AVONEX	-2.16 %	-
AVONEX U S	-0.09 %	-
AVONEX Rest of World	-6.01 %	-
PLEGRIDY	8.07 %	-
PLEGRIDY U S	0.83 %	-
PLEGRIDY Rest of World	12.99 %	-
TYSABRI	15.73 %	-
TYSABRI U S	20.42 %	-
TYSABRI Rest of World	10.51 %	-
Rare Disease Product Revenue	-1.08 %	-
Rare Disease Product Revenue U S	-2.81 %	-
Rare Disease Product Revenue Rest of World	0.12 %	-
SPINRAZA	-11.77 %	-
SPINRAZA U S	-7.9 %	-
SPINRAZA Rest of World	-13.99 %	-
SKYCLARYS	21.63 %	-
SKYCLARYS U S	3.91 %	-
SKYCLARYS Rest of World	43.98 %	-
QALSODY	109.68 %	-
QALSODY U S	40 %	-
QALSODY Rest of World	175 %	-
Biosimilars	0.77 %	-
Biosimilars Rest of World	3.23 %	-
BENEPALI	9.7 %	-
BENEPALI Rest of World	9.7 %	-
IMRALDI	4.64 %	-
IMRALDI Rest of World	4.64 %	-
FLIXABI	-19.85 %	-
FLIXABI Rest of World	-19.85 %	-
Other	88.44 %	-
Other U S	96.8 %	-
Other Rest of World	-92.31 %	-
ZURZUVAE	100 %	-
ZURZUVAE U S	99.64 %	-
ZURZUVAE Rest of World	-	-
Alzheimer s collaboration revenue	80.3 %	-
Alzheimer s Collaboration	80.3 %	-
Distributor One	5.41 %	-
Distributor Two	4.26 %	-
Genentech	26.32 %	-
Royalty Attributed To OCREVUS	9.83 %	-
Revenue from anti-CD20 therapeutic programs	10.81 %	-
Contract manufacturing revenue	-15.98 %	-
Royalty and other revenue	-11.82 %	-
Contract manufacturing royalty and other revenue	-15.82 %	-
Reportable Segment	1.93 %	-
Total	1.93 %	-

Q1 three months ended (Mar 31 2026)
Income by Business Segments	Income (in millions $)	% (Profit Margin)
Total	319.50	12.89 %

Q1 three months ended (Mar 31 2026)
Income Growth rates by Segment	Y/Y Income %	Q/Q Income %
Total	32.85 %	-

Annual Report on Biogen Inc Divisions, Sales by Country


Product revenue net	71.98 %	of total Revenue
Product revenue net U S	35.87 %	of total Revenue
TECFIDERA	6.87 %	of total Revenue
VUMERITY	7.55 %	of total Revenue
AVONEX	7.03 %	of total Revenue
PLEGRIDY	2.53 %	of total Revenue
TYSABRI	16.84 %	of total Revenue
SPINRAZA	15.64 %	of total Revenue
SKYCLARYS	5.26 %	of total Revenue
QALSODY	0.88 %	of total Revenue
BENEPALI	4.58 %	of total Revenue
IMRALDI	1.92 %	of total Revenue
FLIXABI	0.53 %	of total Revenue
Other	1.99 %	of total Revenue
ZURZUVAE	1.97 %	of total Revenue
Alzheimer s collaboration revenue	1.8 %	of total Revenue
Distributor One	0 %	of total Revenue
Distributor Two	0 %	of total Revenue
Genentech	0.26 %	of total Revenue
Revenue from anti-CD20 therapeutic programs	18.81 %	of total Revenue
Contract manufacturing revenue	6.87 %	of total Revenue
Royalty and other revenue	0.54 %	of total Revenue
Contract manufacturing royalty and other revenue	7.41 %	of total Revenue
Reportable Segment	100 %	of total Revenue
BYOOVIZ	0.33 %	of total Revenue
TOFIDENCE	0.01 %	of total Revenue
FUMADERM And ADUHELM	0.02 %	of total Revenue
Total Fumarate	14.42 %	of total Revenue
Total Interferon	9.56 %	of total Revenue
Subtotal Multiple Sclerosis	40.84 %	of total Revenue
FAMPYRA 1	0.01 %	of total Revenue
Subtotal Rare Disease	21.78 %	of total Revenue
Subtotal Biosimilars	7.37 %	of total Revenue
Total product revenue net	71.98 %	of total Revenue
United States Total Fumarate	8.29 %	of total Revenue
United States TECFIDERA	1.7 %	of total Revenue
United States VUMERITY	6.58 %	of total Revenue
United States Total Interferon	5.94 %	of total Revenue
United States AVONEX	4.88 %	of total Revenue
United States PLEGRIDY	1.06 %	of total Revenue
United States Subtotal Multiple Sclerosis	23.99 %	of total Revenue
United States TYSABRI	9.76 %	of total Revenue
United States Subtotal Rare Disease	9.77 %	of total Revenue
United States SPINRAZA	6.32 %	of total Revenue
United States SKYCLARYS	3.14 %	of total Revenue
United States QALSODY	0.3 %	of total Revenue
United States Subtotal Biosimilars	0.14 %	of total Revenue
United States BYOOVIZ	0.13 %	of total Revenue
United States TOFIDENCE	0.01 %	of total Revenue
United States Other	1.98 %	of total Revenue
United States ZURZUVAE	1.97 %	of total Revenue
United States FUMADERM And ADUHELM	0 %	of total Revenue
United States Total product revenue net	35.87 %	of total Revenue
Rest of World Total Fumarate	6.14 %	of total Revenue
Rest of World TECFIDERA	5.17 %	of total Revenue
Rest of World VUMERITY	0.97 %	of total Revenue
Rest of World Total Interferon	3.62 %	of total Revenue
Rest of World AVONEX	2.15 %	of total Revenue
Rest of World PLEGRIDY	1.47 %	of total Revenue
Rest of World Subtotal Multiple Sclerosis	16.85 %	of total Revenue
Rest of World TYSABRI	7.08 %	of total Revenue
Rest of World FAMPYRA 1	0.01 %	of total Revenue
Rest of World Subtotal Rare Disease	12.01 %	of total Revenue
Rest of World SPINRAZA	9.31 %	of total Revenue
Rest of World SKYCLARYS	2.12 %	of total Revenue
Rest of World QALSODY	0.57 %	of total Revenue
Rest of World Subtotal Biosimilars	7.23 %	of total Revenue
Rest of World BENEPALI	4.58 %	of total Revenue
Rest of World IMRALDI	1.92 %	of total Revenue
Rest of World FLIXABI	0.53 %	of total Revenue
Rest of World BYOOVIZ	0.2 %	of total Revenue
Rest of World Other	0.02 %	of total Revenue
Rest of World FUMADERM And ADUHELM	0.02 %	of total Revenue
Rest of World Total product revenue net	36.11 %	of total Revenue
Discounts	8.42 %	of total Revenue
Contractual Adjustments	28.04 %	of total Revenue
Returns	0.32 %	of total Revenue
Reduction of accounts receivable	10.11 %	of total Revenue
Royalty revenue on sales of OCREVUS	14.31 %	of total Revenue
Product revenue net Reportable Segment	71.98 %	of total Revenue
Product revenue net U S Reportable Segment	35.87 %	of total Revenue
Product revenue net Europe Reportable Segment	18.92 %	of total Revenue
Product revenue net Germany Reportable Segment	8.62 %	of total Revenue
Product revenue net Asia Reportable Segment	4.24 %	of total Revenue
Product revenue net Other Reportable Segment	4.33 %	of total Revenue
Revenue from anti-CD20 therapeutic programs Reportable Segment	18.81 %	of total Revenue
Revenue from anti-CD20 therapeutic programs U S Reportable Segment	17.95 %	of total Revenue
Revenue from anti-CD20 therapeutic programs Europe Reportable Segment	0.02 %	of total Revenue
Revenue from anti-CD20 therapeutic programs Other Reportable Segment	0.84 %	of total Revenue
Contract manufacturing royalty and other revenue Reportable Segment	7.41 %	of total Revenue
Contract manufacturing royalty and other revenue U S Reportable Segment	4.19 %	of total Revenue
Contract manufacturing royalty and other revenue Europe Reportable Segment	0.11 %	of total Revenue
Contract manufacturing royalty and other revenue Asia Reportable Segment	3.11 %	of total Revenue
Reportable Product revenue net	71.98 %	of total Revenue

Twelve months ended 2025
BIIB s Annual Revenue by Geography and Business Segments	Sales (in millions $)	% (of total Sales)
Product revenue net	7,119.40	71.98 %
Product revenue net U S	3,547.90	35.87 %
TECFIDERA	679.70	6.87 %
VUMERITY	746.80	7.55 %
AVONEX	695.50	7.03 %
PLEGRIDY	250.10	2.53 %
TYSABRI	1,665.40	16.84 %
SPINRAZA	1,546.80	15.64 %
SKYCLARYS	520.50	5.26 %
QALSODY	86.90	0.88 %
BENEPALI	453.20	4.58 %
IMRALDI	190.20	1.92 %
FLIXABI	52.60	0.53 %
Other	197.20	1.99 %
ZURZUVAE	195.10	1.97 %
Alzheimer s collaboration revenue	177.70	1.8 %
Distributor One	0.00	0 %
Distributor Two	0.00	0 %
Genentech	25.50	0.26 %
Revenue from anti-CD20 therapeutic programs	1,860.60	18.81 %
Contract manufacturing revenue	679.40	6.87 %
Royalty and other revenue	53.50	0.54 %
Contract manufacturing royalty and other revenue	732.90	7.41 %
Reportable Segment	9,890.60	100 %
Total	9,890.60	100 %
BYOOVIZ	32.40	0.33 %
TOFIDENCE	0.70	0.01 %
FUMADERM And ADUHELM	2.10	0.02 %
Total Fumarate	1,426.50	14.42 %
Total Interferon	945.60	9.56 %
Subtotal Multiple Sclerosis	4,038.90	40.84 %
FAMPYRA 1	1.40	0.01 %
Subtotal Rare Disease	2,154.20	21.78 %
Subtotal Biosimilars	729.10	7.37 %
Total product revenue net	7,119.40	71.98 %
United States Total Fumarate	819.70	8.29 %
United States TECFIDERA	168.50	1.7 %
United States VUMERITY	651.20	6.58 %
United States Total Interferon	587.80	5.94 %
United States AVONEX	482.90	4.88 %
United States PLEGRIDY	104.90	1.06 %
United States Subtotal Multiple Sclerosis	2,372.50	23.99 %
United States TYSABRI	965.00	9.76 %
United States Subtotal Rare Disease	966.20	9.77 %
United States SPINRAZA	625.50	6.32 %
United States SKYCLARYS	310.60	3.14 %
United States QALSODY	30.10	0.3 %
United States Subtotal Biosimilars	13.70	0.14 %
United States BYOOVIZ	13.00	0.13 %
United States TOFIDENCE	0.70	0.01 %
United States Other	195.50	1.98 %
United States ZURZUVAE	195.10	1.97 %
United States FUMADERM And ADUHELM	0.40	0 %
United States Total product revenue net	3,547.90	35.87 %
Rest of World Total Fumarate	606.80	6.14 %
Rest of World TECFIDERA	511.20	5.17 %
Rest of World VUMERITY	95.60	0.97 %
Rest of World Total Interferon	357.80	3.62 %
Rest of World AVONEX	212.60	2.15 %
Rest of World PLEGRIDY	145.20	1.47 %
Rest of World Subtotal Multiple Sclerosis	1,666.40	16.85 %
Rest of World TYSABRI	700.40	7.08 %
Rest of World FAMPYRA 1	1.40	0.01 %
Rest of World Subtotal Rare Disease	1,188.00	12.01 %
Rest of World SPINRAZA	921.30	9.31 %
Rest of World SKYCLARYS	209.90	2.12 %
Rest of World QALSODY	56.80	0.57 %
Rest of World Subtotal Biosimilars	715.40	7.23 %
Rest of World BENEPALI	453.20	4.58 %
Rest of World IMRALDI	190.20	1.92 %
Rest of World FLIXABI	52.60	0.53 %
Rest of World BYOOVIZ	19.40	0.2 %
Rest of World Other	1.70	0.02 %
Rest of World FUMADERM And ADUHELM	1.70	0.02 %
Rest of World Total product revenue net	3,571.50	36.11 %
Discounts	832.40	8.42 %
Contractual Adjustments	2,773.10	28.04 %
Returns	31.90	0.32 %
Reduction of accounts receivable	1,000.40	10.11 %
Royalty revenue on sales of OCREVUS	1,414.90	14.31 %
Product revenue net Reportable Segment	7,119.40	71.98 %
Product revenue net U S Reportable Segment	3,547.90	35.87 %
Product revenue net Europe Reportable Segment	1,871.60	18.92 %
Product revenue net Germany Reportable Segment	853.00	8.62 %
Product revenue net Asia Reportable Segment	419.10	4.24 %
Product revenue net Other Reportable Segment	427.80	4.33 %
Revenue from anti-CD20 therapeutic programs Reportable Segment	1,860.60	18.81 %
Revenue from anti-CD20 therapeutic programs U S Reportable Segment	1,775.40	17.95 %
Revenue from anti-CD20 therapeutic programs Europe Reportable Segment	1.80	0.02 %
Revenue from anti-CD20 therapeutic programs Other Reportable Segment	83.40	0.84 %
Contract manufacturing royalty and other revenue Reportable Segment	732.90	7.41 %
Contract manufacturing royalty and other revenue U S Reportable Segment	414.70	4.19 %
Contract manufacturing royalty and other revenue Europe Reportable Segment	10.80	0.11 %
Contract manufacturing royalty and other revenue Asia Reportable Segment	307.40	3.11 %
Reportable Product revenue net	7,119.40	71.98 %

Twelve months ended 2025
BIIB s Annual Income by Country and Business Segments	Income (in millions $)	% (Profit Margin)
Total	1,292.90	13.07 %

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments	% Y/Y Sales Growth	% Y/Y Income Growth
Product revenue net	-1.3 %	-
Product revenue net U S	9.59 %	-
TECFIDERA	-29.72 %	-
VUMERITY	18.92 %	-
AVONEX	-1.7 %	-
PLEGRIDY	-3.99 %	-
TYSABRI	-2.89 %	-
SPINRAZA	-1.68 %	-
SKYCLARYS	36.08 %	-
QALSODY	168.21 %	-
BENEPALI	-5.41 %	-
IMRALDI	-10.75 %	-
FLIXABI	-16.77 %	-
Other	139.03 %	-
ZURZUVAE	170.22 %	-
Alzheimer s collaboration revenue	196.66 %	-
Distributor One	8.11 %	-
Distributor Two	17.91 %	-
Genentech	38.59 %	-
Revenue from anti-CD20 therapeutic programs	6.33 %	-
Contract manufacturing revenue	14.74 %	-
Royalty and other revenue	-11.57 %	-
Contract manufacturing royalty and other revenue	12.3 %	-
Reportable Segment	2.22 %	-
Total	2.22 %	-20.79 %
FAMPYRA	-	-
BYOOVIZ	-11.48 %	-
TOFIDENCE	-36.36 %	-
FUMADERM And ADUHELM	-79.61 %	-
Total Fumarate	-10.57 %	-
Total Interferon	-2.31 %	-
Subtotal Multiple Sclerosis	-7.15 %	-
FAMPYRA 1	-98.05 %	-
Subtotal Rare Disease	8.35 %	-
Subtotal Biosimilars	-8.07 %	-
Total product revenue net	-1.3 %	-
United States Total Fumarate	15.81 %	-
United States TECFIDERA	-0.41 %	-
United States VUMERITY	20.91 %	-
United States Total Interferon	4.46 %	-
United States AVONEX	7 %	-
United States PLEGRIDY	-5.83 %	-
United States Subtotal Multiple Sclerosis	8.31 %	-
United States TYSABRI	4.89 %	-
United States Subtotal Rare Disease	1.95 %	-
United States SPINRAZA	-0.03 %	-
United States SKYCLARYS	3.16 %	-
United States QALSODY	44.02 %	-
United States Subtotal Biosimilars	-43.15 %	-
United States BYOOVIZ	-43.48 %	-
United States TOFIDENCE	-36.36 %	-
United States Other	160.67 %	-
United States ZURZUVAE	170.22 %	-
United States FUMADERM And ADUHELM	-85.71 %	-
United States Total product revenue net	9.59 %	-
Rest of World Total Fumarate	-31.61 %	-
Rest of World TECFIDERA	-35.93 %	-
Rest of World VUMERITY	6.94 %	-
Rest of World Total Interferon	-11.72 %	-
Rest of World AVONEX	-17.02 %	-
Rest of World PLEGRIDY	-2.62 %	-
Rest of World Subtotal Multiple Sclerosis	-22.83 %	-
Rest of World TYSABRI	-11.9 %	-
Rest of World FAMPYRA 1	-98.05 %	-
Rest of World Subtotal Rare Disease	14.19 %	-
Rest of World SPINRAZA	-2.77 %	-
Rest of World SKYCLARYS	157.86 %	-
Rest of World QALSODY	393.91 %	-
Rest of World Subtotal Biosimilars	-6.97 %	-
Rest of World BENEPALI	-5.41 %	-
Rest of World IMRALDI	-10.75 %	-
Rest of World FLIXABI	-16.77 %	-
Rest of World BYOOVIZ	42.65 %	-
Rest of World Other	-77.33 %	-
Rest of World FUMADERM And ADUHELM	-77.33 %	-
Rest of World Total product revenue net	-10.18 %	-
Discounts	0.99 %	-
Contractual Adjustments	3.19 %	-
Returns	35.17 %	-
Reduction of accounts receivable	6.71 %	-
Royalty revenue on sales of OCREVUS	5.63 %	-
Product revenue net Reportable Segment	-1.3 %	-
Product revenue net U S Reportable Segment	9.59 %	-
Product revenue net Europe Reportable Segment	-13.81 %	-
Product revenue net Germany Reportable Segment	-10.74 %	-
Product revenue net Asia Reportable Segment	14.23 %	-
Product revenue net Other Reportable Segment	-11.28 %	-
Revenue from anti-CD20 therapeutic programs Reportable Segment	6.33 %	-
Revenue from anti-CD20 therapeutic programs U S Reportable Segment	6.08 %	-
Revenue from anti-CD20 therapeutic programs Europe Reportable Segment	200 %	-
Revenue from anti-CD20 therapeutic programs Other Reportable Segment	10.17 %	-
Contract manufacturing royalty and other revenue Reportable Segment	12.3 %	-
Contract manufacturing royalty and other revenue U S Reportable Segment	4.99 %	-
Contract manufacturing royalty and other revenue Europe Reportable Segment	2600 %	-
Contract manufacturing royalty and other revenue Asia Reportable Segment	19.52 %	-
Reportable Product revenue net	-1.3 %	-
Rest of World FAMPYRA	-	-

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.